Skip to main content

Market Overview

Clovis Shares Reiterated As A Sell Following 10% Rally

Share:

AstraZeneca plc (ADR) (NYSE: AZN) on Tuesday presented positive Lynparza results in ovarian cancer maintenance. This raises competitive risks for Clovis Oncology Inc’s (NASDAQ: CLVS) Rubraca, which is currently in the phase III ARIEL3 maintenance study, Chardan Capital Markets’ Madhu Kumar said in a report.

Madhu reiterated a Sell rating for Clovis, with a price target of $36.

Increased Competition

Clovis is expected to present top-line results from Rubraca’s phase III ARIEL3 maintenance study in mid-2017.

“While we understand that success for a second PARPi in the setting of ovarian cancer maintenance therapy arguably further de-risks PARPi as a class in the indication, this de-risking needs to be balanced by the competitive pressures generated by multiple effective PARPis in the ovarian cancer space,” Madhu wrote.

Related Link: Wall Street's M&A Chatter From March 10-12

Moreover, positive results for competitors in the second-line maintenance setting exerts pressure on Rubraca's approved indication of third line or later therapy. The analyst added that the positive SOLO-2 result presented by AstraZeneca “raises the possible risk” of ARIEL3 failing in an absolute or relative sense.

Although Rubraca is being tested for another major indication, that of metastatic castrate-resistant prostate cancer, there are several PARPi competitors in development in combination with AR [androgen receptor] inhibitors, Madhu noted.

Latest Ratings for CLVS

DateFirmActionFromTo
May 2021HC Wainwright & Co.MaintainsBuy
Nov 2020SVB LeerinkMaintainsUnderperform
Nov 2020HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for CLVS
View the Latest Analyst Ratings

 

Related Articles (CLVS)

View Comments and Join the Discussion!

Posted-In: Chardan Capital Markets Madhu Kumar RubracaAnalyst Color Short Ideas Reiteration Analyst Ratings Trading Ideas

Latest Ratings

StockFirmActionPT
PHXSeaport GlobalInitiates Coverage On
AFCGLake StreetInitiates Coverage On29.0
OSSNoble Capital MarketsUpgrades7.0
NCNOGabelli & Co.Upgrades
HAECJS SecuritiesUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com